The cyclin-dependent kinase 4-inhibitor (CDK41; p16; or MTS1) gene has been proposed as a candidate for a tumorsuppressor gene located in chromosome 9p21, a frequently deleted region in a wide spectrum of human cancers, including leukemias. Recent studies disclosed that it was frequently deleted or mutated in a variety of primary human cancers, including acute lymphoblastic leukemia. The purpose of this study is t o figure out the precise manners and frequencies of p16 gene inactivation in diverse hematopoietic tumor types and thus t o clarify its significance in development of human hematopoietic malignancies. A total of 410 tumor specimens from patients with primary hematopoietic malignancies were examined for deletions of the p16 gene as well as the neighboring p15 gene and the nearby interferon a gene by Southern blot analysis. Tumor-specific mutations or small deletions of the p16 gene were also studied in 74 patients using single-strand conformation polymorphism analysis and direct sequencing. Loss of the p16 gene was most frequently observed among the three genes examined and was found in 59 of the 410 patients: 2 of 134 with T HE CONCEPT OF tumor-suppressor genes is one of the mainstreams of our current understandings of oncogenesis.'.2 Loss of their intrinsic tumor-suppressor functions
acute myelocytic leukemia, 41 of 105 with acute lymphocytic leukemia, 2 of 15 with chronic lymphocytic leukemia, 5 of 14 with adult T-cell leukemia, 4 of 33 with non-Hodgkin's lymphoma, 3 of 8 with mixed-lineage leukemia, and 2 of 61 with chronic myelocytic leukemia. In 16 of the 59 patients, the p16 deletions occurred due t o rearrangements within the small region between the p15 exon 2 and the p16 exon 2. Tumor-specific mutations or small deletions of the p16 gene were not detected in the 74 patients examined, including 12 of 14 patients with hemizygous deletions of the gene. is thought to contribute to unregulated cell growth and tumor formation. Chromosome 9p21 has been supposed to be a hot spot containing a tumor-suppressor gene because deletion of this locus was reported to occur in a variety of human cancers, including leukemia,'" bladder cancer,""' non-small-cell lung cancer,'3 ovarian cancer,I4 mesothelioma,I5 and malignant m e l a n~m a . '~. '~ In addition, some of these tumors were reported to show loss of heterozygosity (LOH) of this I o c u s , '~~'~ and linkage analyses of familial melanoma kindreds pinpointed the locus for a putative melanoma susceptible gene to 9~2 1 .~* ,~'
In this context, the p16 gene, which was originally identified as a gene for an inhibitor of the cyclin Dkyclin-dependent kinase 4 (CDK4) complex, has emerged as an attractive candidate for the tumorsuppressor gene settled in this locus because of its negative regulatory role in G1 to S entry in cell cycle ~o n t r o l . '~~~~ In initial reports, the p16 gene was shown to be deleted with a surprisingly high frequency in cell lines derived from a varety of human cancer^.*^.'^ In a previous study of our own, up to 38% of human leukemia cell lines underwent p16
deletions andor re arrangement^.^^ However, before it is established as a tumor-suppressor gene in 9p21 generally involved in human carcinogenesis, including leukemias, deletions and/or mutations of the p16 gene in primary tumors should be evaluated more carefully and extensively. Recently, deletions and point mutations of the p16 gene have been reported in several types of primary human cancers,?o -37 In the previous study, we showed that homozygous deletions of the p16 gene had occurred in 4 of 14 cases with primary acute lymphocytic leukemia (ALL).25 Later, several investigators also reported that p 16 deletions frequently OCcurred in primary ALL. 38 .'" Although we observed in leukemia cell lines p1 6 gene deletions in every lineage of hemato- poiesis, none of patients with acute myelocytic leukemia (AML) and chronic myelocytic leukemia (CML) in blastic crisis had showed deletions of this gene in our first study. Loss of the p16 gene, therefore, seemed to preferentially occur in ALL among primary leukemias. However, because we did not evaluate point mutations or small deletions in that study, the precise frequency and the disease specificity of p16 gene inactivation remained to be determined. More importantly, there exist controversies about its role as a tumor-suppressor gene in other primary cancers, which might also be discussed in cases of leukemias. The frequencies of homozygous deletions and mutations of the p16 gene seem to be too low in some types of primary tumors such as bladder cancer to come up to the high LOH rates observed in the 9p21 locus of those tumors, if it is a bona fide tumorsuppressor gene in this locus.36~37~40 To clarify the significance of p16 gene inactivation and its disease specificity among human hematologic malignancies, we thus have conducted a multicenter cooperative study in which configurations of the p16 gene as well as those of the adjacent p15 and interferon a (IFNa) genes were examined by Southern blot analysis in 410 patients with primary hematopoietic tumors. In 74 of the 410 patients, we also studied for mutations or small deletions of the p16 gene using polymerase chain reaction single-stranded conformation polymorphism (PCR-SSCP) and direct sequencing.
MATERIALS AND METHODS
Patients and samples. Sixty-four medical centers and hospitals in Japan participated in this collaborative study promoted by the Japan leukemia study group of the Ministry of Health and Welfare, Japan. A total of 410 patients with hematopoietic malignant disorders admitted to these collaborating centers and hospitals between April 1988 and September 1994 were included in this study after informed consent was obtained. Diagnoses of the patients were AML, ALL, mixed-lineage leukemia (Mixed AL), adult T-cell leukemia (ATL), CML, chronic lymphocytic leukemia (CLL), myelodysplastic syndrome (MDS) with or without acute transformation, multiple myeloma (MM), and non-Hodgkin's lymphoma (NHL). AMLs were further diagnosed as MO to M7 according to the French-AmericanBritish (FAB) classification criteria!'+' ALLs were also subclassified according to immunophenotypic markers as null ALLs, B-precursor ALLs, B-ALLs, and T-ALLs.~' ALLs classified in early preB, preB, and common ALLs in the literature were collectively described here as B-precursor ALLs in this study. Samples were bone marrow or peripheral blood mononuclear cells separated on Ficoll-Hypaque density gradient or lymph node biopsy specimens. Cells were freshly prepared from patients or stored in 10% dimethylsulfoxide at -70°C or in liquid nitrogen before DNA extraction and subsequent analysis. Clinical data at the time of sampling include age, sex, white blood cell (WBC) count, percentage of blasts in the sample, and, if available, results of surface maker analyses, cytogenetic studies, and studies for rearrangements of the T-cell receptor and Ig genes. The therapeutic outcomes of patients were retrospectively incorporated into the results of this study.
PCR reaction and DNA probes. To obtain probes for Southern blot analysis of the p16, p15, and IFNa genes, we performed PCR and reverse transcriptase-PCR (RT-PCR) with genomic DNA and total RNA from normal bone marrow as templates, respectively. A primer set and reaction conditions of RT-PCR for amplifying a p16 cDNA probe, PR16, were previously described." For SSCP and direct sequencing analysis, we amplified two genomic fragments, 16EX1 (nucleotides [nt] 61-340, 280 bp), containing exon 1 of the p16 gene, and 16EX2 (nt 81-539, 459 bp), containing exon 2 of the p16 gene. Because 16EX2 probe contains highly homologous sequences to exon 2 of the p15 gene and cross-hybridizes to this gene, we digested PR16 fragment with Kpn I endonuclease and obtained a probe, PR16KPN, specific to the p16 gene. Sequences of the p16 and p15 genes were derived from Genbank and nucleotide numbers were cited according to this data base.22-24. 46 Primer sequences used to amplify these probes were as follows: A primer set for this probe is 5'-ACCTGGTTATATGTTGCCTTC-3' and 5"CAATTACATGTT-GAAGTCAGTTTA-3'. PCR reactions for amplification of 16EXI and 16EX2 were performed in a reaction mixture containing 10 mmoVL Tris-HC1 (pH 9.2), 50 mmol/L KC1, 3.5 mmol/L MgCI,, 0.01% bovine serum albumin (BSA), 200 pmol/L dNTPs, 5% dimethylsulfoxide, 15% glycerol, 1 pmoVL each of two PCR primers, and 2.5 U Taq DNA polymerase (Perkin-Elmer, Norwalk, CT). The PCR was repeated for 50 cycles of 94°C (1 minute), 55°C (I minute), and 72°C (2 minutes). The reaction condition of PCR for IFN8 was 50 cycles of 94°C (1 minute), 55°C (1 minute), and 72°C (2 minutes) in a reaction mixture containing IO mmol/L Tris-HC1 (pH 9.2), 50 mmoVL KC1, 1.5 mmol/L MgC12, 1 pnol/L each of two PCR primers, and 2.5 U Taq DNA polymerase. All PCR products were subcloned into plasmid vectors and sequenced. C6E5H2 probe that recognizes the AMLl gene was a kind gift from M. Ohki (Radiology Division, National Cancer Research Institute, Tokyo, Japan) and was used for confirming the integrity of the DNA samples and for calibrating the intensities of signals of the target genes in Southern blot analysis.
Southern blot analysis. The procedures for Southern blot analysis were essentially identical to those previously de~cribed.2~ Hind111 endonuclease was used for DNA digestion. PR16, IFN8, C6E5H2, and, if necessary, 16EX1 and PR16KPN were used as probes. Filters were subjected to deprobing procedures among repetitive uses and used for rehybridization with another probe. Homozygous or hemizygous deletion of the p15, p16, and IFNa genes was determined by visual inspection of autoradiograms compared with AMLl signals used as internal controls. For an objective estimation of gene dosage to classify patients as having homozygous or hemizygous deletions, radioactivities of the interest bands on autoradiograms were measured by the BAS2000 image analyzer (Fuji Film, Tokyo, Japan). The measured radioactivities were standardized by using those of AMLl signals as controls.
SSCP analysis and direct sequencing. The Fastsystem (Pharmacia, Uppsala, Sweden) was used in semiautomated SSCP analyses. From the DNA samples of the patients, 16EX1 and 16EX2 were amplified, denatured in 96% formamide and 20 mmol/L EDTA at 95°C for 5 minutes, and electrophoresed through 20% nondenaturing homogenous gels for 300 V h. DNAs were visualized by silver staining as described in the instruction manual of the system. Genomic DNAs from Hela and P39 TSU cells were used as positive controls for analysis of the 16EX1 and the 16EX2, respectively.
PCR-amplified 16EXl and 16EX2 fragments were directly sequenced using the Sequenase PCR Product Sequencing Kit (Amersham International plc, Buckinghamshire, UK) according to the manufacturer's instructions. Sequencing primers used were 5'-CTAAGGTTAAGGGGACGTTTG-3' for 16EX1, and 5'-GGC-TGAACTITCTGTGCTGGA-3' and 5'-TCCTTTCCGTCATGCC-GGCCCCCA-3' for 16EX2.
RESULTS
Characteristics of patient population and karyotypes. Of the 410 patients studied, 259 were male and 15 1 were female. The number of patients analyzed by SSCP and direct sequencing is in brackets. The number of patients with homozygous deletion is in parentheses. Table 1 ). In 344 patients, the blast contents of the samples exceeded 70%. Although blast contents tend to be much lower in CML and MDS patients, these are considered to be clonal disorders and were included in the study. Cytogenetic data at the time of sample collection were available in 306 patients. One hundred six patients had normal karyotypes. 
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ConJgurations of the p16 gene by Southern blot analysis. In Southern blot analysis with PR16 as a probe, three distinct bands 20, 12, and 6 kb in size were identified. Because the p16 gene is highly homologous to the p15 gene,2s.4h we further hybridized the filters separately with the gene-specific probes 16EX1 and PR16KPN.
By using these specific probes, it was shown that the 6-, 12-, and 20-kb bands contained the p16 exon 1, the p16 exon 2, and the p15 exon 2, respectively (data not shown). Based on these observations, we could easily evaluate the loss of the p16 and/or p15 genes separately with a single hybridization procedure with PR1 6 as a probe. The normal IFNa gene cluster was detected as 5 distinct bands because of multiple homologous sequences clustering in chromosome 9p21. The 9p21 locus underwent gene deletions in a variety of fashions. Representative blots are shown in Fig 1. Homozygous deletions involving all three genes (Fig IA, lanes 2 and 3) , exon 2 of the p15 gene and exon 1 of the p16 gene (Fig lA, lane 7) , and both exons of the p16 gene with intact exon 2 of the p15 gene (Fig IA,  lane 5 ). Some cases showed gene rearrangements and/or deletions of the p16 gene with or without involvement of the IFNa gene (Fig lB, lanes 2 and 5) . Others had hemizygous deletion of this loci (Fig lB, lane 4) . The results are summarized in Tables 1 and 2 .
In total, the p16 gene was found to be deleted and/or rearranged in 59 of 410 patients and 45 patients showed homozygous deletions. Although blast contents exceeded 70% of the analyzed cells in 344 samples and mononuclear cells were concentrated by Ficoll-Hypaque density gradient, significant contaminations of normal cells inevitablely occurred in samples. Therefore, we could not determine homozygosity or heterozygosity of the deletions in cases with lower blast contents. Because we did not take these possible contaminations in such cases into considerations upon interpretation of Southern blot, we might underestimate the frequencies of homozygous or heterozygous deletions and the real rates of p16 deletions may be somewhat higher. Diagnoses of patients who lost the p16 gene were highly restricted to lymphoid tumors, with only 5 exceptional cases (2 with AML and 3 with Mixed AL; patients no. 12 through 15 and 59); notably, leukemic cells of 3 of the 5 patients expressed lymphoid markers in addition to myeloid markers. p16 deletions were observed in 2 of 134 patients with AML, 41 of 105 patients with ALL, 2 of 15 patients with CLL, 2 (lymphoid crisis) of 61 patients with CML, 5 of 14 patients with ATL, 4 of 33 patients with NHL (including 1 patient with Sezary syndrome), and 3 of 8 patients with Mixed AL. p16 deletion was especially frequent in ALL (41/105 [39%]) and was found in all subtypes of ALLs. Although low numbers of patients with B-ALL and null ALL prevented us from statistically showing a significant difference in incidence of p16 deletions between B-precursor ALL and these ALL subtypes, the frequency of p16 deletions in T-cell ALL, CLL, and NHL seems rather lower than that in B-precursor ALL ( P = ,0307, .0418, and .0031, respectively). Because the rearranged bands of the p16 gene were detected in patients no. IO, 15, 21, 25, 39, and 44 (see Fig 1 for patient no. 44 ; data not shown for the other patients) with 16EX1 probe, the breakpoints of rearrangements in these patients should be within IO kb from exon 1 to the p16 gene.
For In 53 of 410 patients, one or both alleles of the p15 gene also underwent deletions. In 39 patients it was deleted homozygously. All 53 patients with loss of the p15 gene also showed loss of the p16 gene and all patients with homozygous loss of the p15 gene carried homozygous deletion of the p16 gene as well. In contrast, 5 of 47 patients with homozygous loss of the p16 gene (patients no. 15, 21, 26, 39, and 44) retained one or both alleles of the p15 gene. Sixteen patients lost at least a part of the IFNa gene cluster either homozygously or hemizygously. Fourteen of the 16 patients also had loss of both the p I6 and p15 genes, although the other 2 had deletions of the IFNa gene cluster without any additional loss of the p15 or p16 alleles (Fig IC,  lane l) .
Analysis of the p16 gene conjiguration in relapsed patients. Samples from 3 ALL patients (no. 19, 21, and 24) who had homozygous deletions andlor rearrangements of the p16 gene at the time of recurrence of the disease (Fig 2,  lanes 3, 6, and 8) were further analyzed for configurations of the p16 locus at the time of their first presentation of the disease. Patient no. 19 showed homozygous loss of the p16 gene at the first presentation (Fig 2, lanes 5 and 6) . In contrast, in patient no. 2 1, both alleles of the genes had remained intact at first (Fig 2, lanes 7 and 8) , and in patient no. 24, leukemic cells originally showed hemizygous loss of the p16 gene (Fig 2, lanes 2 and 3) . suggesting that clonal evolution took place during their recurrence courses of the diseases and that a leukemic clone having homozygous loss of the p16 gene became predominant in these cases. It is also worth noting that one allele of the p15 gene remained intact in patient no. 21 at recurrence (Fig 2, lane 8 ,-2,-3,-4.-9,-13,-16,-17,-20  45,XY,+Xp-,-7,-22,lq-.2P-,3p+q-,4p+,6p+q+ Abbreviations: +I+, no deletion; + / -p homozygous deletion; R/-or R/+. gene rearrangement in one allele with or without deletion of the other allele, respectively; CR. complete remission; PR, partial remission; AD, resistant disease; ND, data not informed or no mitoses obtained; PB. peripheral blood; BM. bone marrow; LN. lymph node; AS, ascites.
Examined by SSCP and direct sequencing analysis. 2 and 31, patient no.  l 9 (lanes 5 and 6). and patient  no. 21 (lanes 7 and 8) . Samples both at first presentation (lanes 2, 5, and 7) and in relapse (lanes  3, 6, and 8 ) There existed 49 informative cases with cytogenetic data in 59 patients with p16 deletions. As expected, deletions and/ or rearrangements of the p16 gene were frequently observed in patients with abnormalities involving chromosome 9p (12 of 14 informative cases with 9p21 abnormalities v 37 of 292 informative cases without 9p21 abnormalities; P < .OOOl; Tables 2 and 3) . However, the other 37 patients had loss of the p16 gene without any cytogenetic aberrations involving this locus, and 7 patients with homozygous loss of the p16 gene had abnormalities of chromosome 9p only in one allele ( Table 3) . Submicroscopic deletions of the p16 gene should exist in these cases. There were no other correlations between p16 deletions and specific cytogenetic abnormalities.
DISCUSSION
In this study, we have evaluated configurations of the three distinct gene loci containing the p16, PIS, and IFNa genes extensively enough to clarify the manners and frequencies of gene deletions occurring within the 9p21 locus. We have shown that these genes frequently underwent deletions (in 61 of 410 patients). Because exon 2 of the p15 gene and exons 1 and 2 of the p16 gene are separated from each other only by 40 kb,23.2J it was especially interesting to compare the three Hind111 fragments containing these exons in terms Abbreviations: -I-, homozygous deletion of the p16 gene/9p abnormalities in both alleles; +/-, hemizygous deletion of the p16 gene1 9p abnormalities in one of the two alleles; +/+, no deletions of the p16 genelno 9p abnormalities. of gene deletions. As expected, all three exons were simultaneously deleted in about three fourths (43 of 59) of the patients with deletions in this locus. In the remaining one fourth, deletions took place in a variety of fashions. However, in this category of patients the manners of gene deletions were not completely at random. Notably, p16 deletions were always detected in patients with p15 deletions and were also observed even in patients without any p15 deletions (patients no. S, 8, IS, 26, 39, and 44). Furthermore, breakpoints of the rearrangements responsible for these deletions were segregated in the small regions between p15 exon 2 and p16 exon 2 with a surprisingly high frequency (Fig  3) . These observations strongly suggest that the p16 gene should be a critical gene responsible for deletions of this locus in hematopoietic tumors. In contrast to our previous observations in cell lines in which loss of the p16 gene was found in every cell lineage,'5 p16 gene deletion is highly specific to and frequent in lymphoid malignancies among primary hematopoietic tumors percent in myeloid tumors; P < .OOOl). It prevails in almost all types of lymphoid diseases, including not only ALL but also NHL, CLL, ATL, and CML in lymphoid crisis, suggesting that, in lymphoid cells, some intrinsic mechanisms, such as enhanced recombinase activities, may exist that render the p16 gene (or the 9p21 region) especially susceptible to deletions and/or rearrangements during cell proliferation and/or differentiation. Althogh we found p16 deletions in a cell line established from a myeloma patient (KPMMI, unpublished observation), none of 4 patients with MM showed deletions of the p16 gene. Because the number of patients with MM was low in our analysis, p16 deletions in this category of patients should be further examined to clarify the involvement of the p16 gene in MM. Although p16 deletions were observed in all subtypes of ALL, in our analysis, the incidence of p16 deletions seems to be lower in T-ALL than in B-precursor ALL ( P = .0307). Concerning this point, Hebert et aI3' reported that the p16 gene was deleted in 20 of 24 T ALL patients, whereas Quesnel et al'" found the p16 deletion in only 3 of 12 T-ALL patients. Thus, the possible preference of p16 deletions in T-ALL is still controversial as that of cytogenetical 9p deletion^?^.^" tions that loss of chromosome 9p21 is primarily involved in lymphoid tumors,"""*~"~ our results indicate that deletions of the p16 gene are more prevalent than expected from cytogenetics among these types of tumors, because the majority of patients with p16 deletion did not carry chromosomal abnormalities involving 9~2 1 . It is intriguing that the p16 locus seems to be deleted during tumor recurrence in 2 of the 3 relapsed patients. In these patients, inactivation of the p16 gene may confer growth advantage on tumor cells and may result in the clonal expansion of leukemic cells with homozygous loss of the p16 gene in recurrence.
Abnormalities of pathways of cell cycle regulations have been implicated in tumor generation in such tumors as benign parathyroid tumor, esophageal cancer, breast cancer, and OGAWA ET AL some types of malignant lymphomas, in which overexpression of cyclin D was rep~rted.~".'~ p16 is supposed to be involved in cell cycle control through inhibition of the cyclin D/CDK4 complex, which regulates GI to S phase entry and might prevent cell cycles from turning around in an inappropriate manner.2'.5x Therefore, inactivation of the p16 gene may well contribute to tumor There are accumulated lines of evidence strongly supporting the idea that the p I6 gene could be the tumor-suppressor gene located in 9p21 locus, playing a key role in some types of human primary cancer^.'^-^' High somatic mutation rates of the p16 gene have been reported in esophageal cancer,".27 pancreatic cancer,'x and non-small-cell lung cancer.") In addition, mutation analysis of familial melanoma kindreds showed cosegregation of inherited mutations with tumors.ZJ.Z5 Moreover, there novel experimental findings have recently come from several laboratories regarding the functions of ~16.~'"' They showed that p16 could inhibit Ras-induced cellular proliferation and transformation of cultured rat embryo fibroblasts5" and prevent colony formation of cell lines established from an esophageal cancer and a mesothelioma.h0 p16 also blocks activation of the E2F transcription factor by cyclin Dl." These findings also strongly support the idea that p16 is a real tumor suppressor. Nevertheless, on the other hand, some investigators question its role as a tumorsuppressor gene and assume another-tumor suppressor gene in 9p2 1,3h.37.~0 because, for example, LOH in chromosome 9p21 was recognized in up to 80% of bladder cancer, whereas frequency of deletions and somatic mutations of the p16 gene was too low to explain such a high LOH This seems to be also the cases with brain tumor, head and neck cancer, and other t~mors.~' In another report of some kindreds of familial melanoma, no mutations were detected in victims of melanoma, although the analysis predicted their linkage to 9p21
Similarly, although our results of deletion analysis seem to favor a critical role of the p16 as a tumor suppressor in lymphoid tumors, we failed to detect any mutations or small deletions in the p16 gene even in 12 patients having hemizygous deletion (or LOH) of this locus. Thus, two general points should be issued to be discussed below.
First, why are mutations so rare in some types of tumors, including lymphoid tumors, while others show high mutation rates? Second, how could we explain the mechanism of p16 gene inactivation in cases with hemizygous deletions (or LOH) of this locus, in which we failed to detect any minute mutations in the intact allele? For the first question, we could consider that gene deletion is the predominant mechanism of inactivation of the p16 gene in lymphoid tumors. In our study, homozygous deletions of the p16 gene (45 of 59 cases) were much more frequent than hemizygous deletions of the gene. Similarly, point mutations of the Rb gene seems to be rare in leukemia, whereas homozygous deletions and/or rearrangements of the Rb gene and loss of Rb protein expression with seemingly intact Rb gene were reported?' In this context, three explanations might be possible for the second point. ( l ) Although we tentatively described 14 patients as having hemizygous deletion based on Southern blot analysis, we were not able to exclude the possible heterogeneity among cell population in the samples, even if the content of blast cells exceeded 90%. For instance, there might exist cases in which half of the cells cany homozygous deletion and the remaining half have normal gene configurations. (2) Another possibility is that the other allele of the gene is rendered inactivated by somatic mutations located outside of the regions we examined or by other mechanisms such as the genomic imprinting. (3) The last possibility is that the gene dosage effect might be critically important for its tumor-suppressor function or dominant cell growth, and loss of even one copy of the gene could partially abrogate its intrinsic functions, in which case "two hits" may no longer be required for tumor cells to acquire growth advantage.
Combined with results from previous studies, our findings strongly support that the p16 is a tumor suppressor and is critically involved in lymphoid tumorigenesis. However, we could not exclude a possibility that another essential tumorsuppressor gene(s) might exist near the p16 gene. It deserves mentioning that Holland et a163 identified two independently deleted regions in both sides of the IFNa gene, suggesting the existence of a tumor-suppressor gene for each. Similarly, in our analysis, the mapping of deleted alleles (shown in the bottom of Fig 3) demonstrates that one peak of the deleted region was detected exactly in the p16 gene, whereas patients no. 60 and 61, both of whom have myeloid leukemias, have loss of the IFNa gene without deletions of the p15 or p16 genes, indicating another peak of the deleted region near the IFNa gene. From this standpoint, conflicting results among different tumor types in different reports might be successfully explained by introducing the idea of dual tumor suppressors in the 9p21 locus. Mutations of a putative unidentified tumor-suppressor gene could then account for presently unresolved LOH of 9p21 in such tumors as leukemia and bladder cancer. This point should be addressed in future investigations.
